Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin plus intravenous iron before CABG for reducing perioperative transfusion
IRCT20190121042447N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of erythropoietin and iron sucrose in iron deficiency anemia (IDA) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Perioperative transfusion requirement and Mean number of packed erythrocyte units transfused per patient. Started May 2019; status: completed.
02
Drugs
erythropoietiniron sucrose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on IRCT20190121042447N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190121042447N1.